Transdermal Physostigmine—Absence of Effect on Topographic Brain Mapping

Neufeld, M. Y.; Mawassi, F.; Levy, A.; Treves, T. A.; Korczyn, A. D.

doi:https://doi.org/10.3233/BEN-1993-6105

Behavioural Neurology

On this page

Abstract Copyright Related Articles

Open Access

Volume 6 | Article ID 892685 | https://doi.org/10.3233/BEN-1993-6105

Transdermal Physostigmine—Absence of Effect on Topographic Brain Mapping

M. Y. Neufeld,^1,3F. Mawassi,¹A. Levy,²T. A. Treves,¹and A. D. Korczyn¹

Received01 Mar 1993

Accepted16 Mar 1993

Abstract

Nine patients with primary degenerative dementia (PDD) participated in an open trial of transdermal physostigmine (TPh). In order to evaluate the neurophysiologic effects of TPh, EEG data were recorded and compared at baseline and following 2 months of continuous treatment. There was no significant effect of TPh on EEG spectra in patients with PDD.

Copyright

Copyright © 1993 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation Order printed copies

Views

171

Downloads

713

Citations